USP25 promotes pathological HIF-1-driven metabolic reprogramming and is a potential therapeutic target in pancreatic cancer

Deubiquitylating enzymes (DUBs) play an essential role in targeted protein degradation and represent an emerging therapeutic paradigm in cancer. However, their therapeutic potential in pancreatic ductal adenocarcinoma (PDAC) has not been explored. Here, we develop a DUB discovery pipeline, combining...

Descripción completa

Detalles Bibliográficos
Autores principales: Nelson, Jessica K., Thin, May Zaw, Evan, Theodore, Howell, Steven, Wu, Mary, Almeida, Bruna, Legrave, Nathalie, Koenis, Duco S., Koifman, Gabriela, Sugimoto, Yoichiro, Llorian Sopena, Miriam, MacRae, James, Nye, Emma, Howell, Michael, Snijders, Ambrosius P., Prachalias, Andreas, Zen, Yoh, Sarker, Debashis, Behrens, Axel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018856/
https://www.ncbi.nlm.nih.gov/pubmed/35440539
http://dx.doi.org/10.1038/s41467-022-29684-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9018856/
https://www.ncbi.nlm.nih.gov/pubmed/35440539
http://dx.doi.org/10.1038/s41467-022-29684-9

Ejemplares similares